Closure of persistent macular holes with human recombinant transforming growth factor-beta 2.
To evaluate the efficacy of human recombinant transforming growth factor-beta 2 (TGF-beta 2) in the closure of persistent macular holes. Retina service at a university-affiliated hospital in Vancouver. Seventeen patients with macular holes who had previously undergone vitrectomy, posterior cortical vitreous removal and prolonged gas tamponade, with failure to close the hole. Treatment with TGF-beta 2 followed by gas tamponade. Closure of macular hole (defined as complete absence of the surrounding neurosensory detachment). Of the 17 holes 16 (94%) were closed. The average improvement in Snellen acuity was 1.76 lines; nine patients (53%) had at least two lines of improvement. The patients who gained two or more lines of acuity following surgery with TGF-beta 2 had lost significantly more lines of acuity with the primary procedure (p = 0.008) and had worse Snellen acuity following the primary procedure (p = 0.0004) than the patients who gained one line or less of acuity following surgery with TGF-beta 2. Among the patients with a final visual acuity of 20/80 or better the average duration of the hole from the onset of symptoms to the second procedure was 22.2 months. Treatment with TGF-beta 2 is a potentially useful adjuvant in the closure of persistent macular holes following failed primary surgery.